MAP2K2 and neoplasm: We tested the MEK-knock-down HCT116 lines in vivo for tumor growth in nude mice and found that silencing both MEK1 and MEK2 together led to a significant delay in tumor growth (Figure 3G), compared to targeting them individually (Figure 3F).